Status | Study |
Terminated |
Study Name: Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome Condition: Myelodysplastic Syndrome (MDS) Date: 2011-08-18 Interventions: Drug: ezatiostat hydrochloride (Telintra®) Three weeks of treatment with ezatiostat at 2000 mg per |
Completed |
Study Name: Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia Condition: Myelodysplastic Syndrome (MDS) Date: 2011-04-13 Interventions: Drug: Azacitidine Azacitidine 75 mg/m2, for 5 days of each 20 day cycle. Transfusional support will be a |
Recruiting |
Study Name: Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome Condition: Myelodysplastic Syndrome Date: 2010-11-17 Interventions: Drug: Lenalidomide Treatment w |
Completed |
Study Name: MORE - Monitoring Revlimid - Collecting of Patient Information From Myelodysplastic Syndrome (MDS) Italian National Registry Condition: Myelodysplastic Syndrome Date: 2010-10-29 Interventions: Drug: lenalidomide Patients who were prescribed Revlimid from 31October 2008 to present. |
Terminated |
Study Name: Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS) Condition: Leukemia Date: 2010-10-14 Interventions: Drug: Lenalidomide 10 mg/day b |
Completed |
Study Name: Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q Condition: Myelodysplastic Syndromes Date: 2010-03-02 Interventions: Drug: Lenalidomide 10 mg d1-d21 of a 28-day cycle Ot |
Active, not recruiting |
Study Name: A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q Condition: Anemia Date: 2009-12-08 Interventions: Drug: Lenalidomide One 10 mg L |
Completed |
Study Name: A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q Condition: Myelodysplastic Syndrome Chronic Myelomonocytic Leukemia A Date: 2009-04-21 Interventions: Drug: Lenalidomide Inducti |
Completed |
Study Name: Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Condition: Adult Acute Basophilic Leukemia Adult Acute Eosinophilic Leukemia Date: 2006-07-13 Interventions: Drug: lenalidomide Given orally Other Names: |
Completed |
Study Name: Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality Condition: Myelodysplastic Syndromes Date: 2005-09-10 Interventions: Drug: Lenalidomide 5 mg Lenali |